Introduction
Infant acute lymphoblastic leukemia (ALL), which is characterized by a high white blood cell count, organomegaly, a high prevalence of central nervous system involvement and poor outcome, appears to belong to a distinct subset of ALL associated with chromosome band 11q23 translocations. [1] [2] [3] The gene on chromosome band 11q23 that is disrupted by these translocations was cloned and designated MLL (or ALL-1 or HRX), 4, 5 which is also associated with secondary acute leukemia in patients who have received topoisomerase II inhibitors for prior neoplasms. [6] [7] [8] The structural features of MLL protein, which is highly homologous to Drosophila trithorax protein, suggest that its normal function may be mediated by a physical interaction with DNA. 9, 10 Although several chromosome loci are involved in reciprocal 11q23 translocations, t(4;11)(q21;q23) is the most common translocation in infant ALL. 11 In acute leukemia with t(4;11)(q21;q23), the MLL gene on 11q23 usually fuses to the AF-4 (or FEL) gene localized on chromosome band 4q21. AF-4 protein, which contains a serine/proline-rich region and a nuclear targeting sequence, has been suggested to function as a transcriptional transactivator. [12] [13] [14] [15] The high serine/proline- rich region of AF-4 is shared with other genes involved in 11q23 translocation, ie the ENL, AF-9 and AFX1 genes, which are fused to MLL in the t(11;19), t(9;11) and t(X;11) loci, respectively. 16, 17 These partner genes have significance regarding the lineage of the acute leukemias. For example, leukemic cells with t(4;11) coexpress lymphoid and myeloid cell surface markers, and those with t(9;11) are usually found in acute myeloid leukemias. 3 These findings strongly suggest that the chimeric protein resulting from the translocation of MLL and its partner gene is involved in the leukemogenesis in patients with acute leukemias. In fact, mice carrying the MLL/AF-9 fusion gene developed acute leukemias. 18 Twins with infant leukemia have been shown to have identical cytogenetics and breakpoints of the MLL gene, and have provided definitive evidence of an intrauterine rearrangement of the MLL gene. [19] [20] [21] An in utero exposure to some drugs and foods which have functional similarity to topoisomerase II inhibitors, and some environmental factors, have also been suggested as affecting the rearrangement of the MLL gene. 1 In the light of these findings, we hypothesized that the MLL rearrangement occurs to some degree even in normal fetuses, and we therefore analyzed the rearrangement of the MLL and AF-4 genes in cord blood samples.
Materials and methods

Materials
Sixty-five healthy full-term newborns were enrolled in this study. After informed consent was obtained from each mother, heparinized cord blood samples were collected at the time of birth. Cord blood mononuclear cells (MNCs) (2 × 10 7 ) were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. Peripheral blood MNCs (1 × 10 7 ) were also isolated from 21 healthy infants or young children. Leukemic cells were obtained from five infants with t(4;11)(q21;q23) acute leukemia at onset. RS 4;11, a leukemic cell line with t(4;11)(q21;q23), was kindly provided by Dr Mel Greaves (Leukaemia Research Fund Centre, London, UK) and maintained in ␣MEM culture medium supplemented with 10% fetal calf serum. The positivity of MLL/AF-4 fusion mRNA had been confirmed in these samples. HEL, a fetal fibroblast cell line, was obtained from the National Children's Medical Research Center, Tokyo, Japan.
RNA preparation and polymerase chain reaction (PCR) for MLL/AF-4 fusion mRNA
Total RNA was isolated from the MNCs and all other samples by the guanidine thiocyanate method as decribed pre-viously. 22 cDNA was synthesized from 1 g of RNA in a 20 l mixture containing 1 g of oligo (dT), 200 U of MMLV-RT (Gibco BRL, Grand Island, NY, USA), 10 mM dithiothreitol, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 0.5 mM of dNTP and 5 U of RNase inhibitor. MLL/AF-4 fusion mRNA was detected by a nested polymerase chain reaction (PCR) as described previously. 23 Briefly, the first-round PCR was performed with cDNA corresponding to 150 ng of RNA in 50 l of a PCR mixture containing 1.25 U of Taq polymerase (Takara, Tokyo, Japan). The primers used for the first-round PCR were as follows; primer-MLLS1 (sense), 5′-TGAGCC-CAAGAAAAAGCAGCCTCCA-3′ located on MLL exon 5 and primer-AF4AS1 (antisense), 5′-CACTTGAACTGCT-CTCGCTCTCTGA-3′ located on AF-4 exon 10 ( Figure 1 ). Amplification was achieved by 35 cycles of denaturation at 95°C for 1 min, annealing at 62°C for 2 min, and elongation at 72°C for 1 min. The second-round PCR was then performed using 3 l of each first PCR product as a template. The primers used for the second-round PCR were as follows; primer-MLLS2 (sense), 5′-GCAAACAGAAAAAAGTGGCTCCCCG-3′ located on MLL exon 6, and primer-AF4AS2 (antisense), 5′-GATGGCTCAGCTGTACTAGGCGTAT-3′ located on AF-4 exon 5 ( Figure 1 ). The amplification profile of the secondround PCR was the same as that of the first-round PCR except for the annealing temperature at 65°C. The integrity of each RNA and following cDNA was checked by PCR using ␤-actin PCR primers. Each PCR product was electrophoresed on a 2.5% agarose gel. The gels were then stained with ethidium bromide and photographed.
Analysis of fusion transcripts of exon 11 and exon 4/5 in AF-4 gene by PCR
To detect the in-frame fusion transcripts of exon 11 and exon 4 or 5 in the AF-4 gene in the cord blood and leukemic samples, we synthesized several sets of primers for AF-4 as follows; primers-AF4S1 (sense), 5′-GGAGGACTATCGA-CAGCAGACCTTT-3′ located on AF-4 exon 3, primer-AF4S2 (sense), 5′-AAGGGGAGCCGCCAGAGGA-3′ located on AF-4 exon 11, and primer-AF4S3 (sense), 5′-CAGGGAAGAAGCA-CAGCTCTGAGA-3′ located on AF-4 exon 11 ( Figure 1 ). Inframe fused AF-4 mRNA was detected by nested PCR as follows: a first-round PCR using primer-MLLS1 or AF4S2 and primer-AF4AS1, and a second-round PCR using primer-AF4S3 and primer-AF4AS2. The PCR mixture and amplification profile were the same as those used for MLL/AF-4 mRNA. As a control for the expression of AF-4 mRNA, a PCR using primer-AF4S1 and primer-AF4AS2 was also performed. 
Sequence analysis
The PCR products eluted from the gel were ligated into pT7Blue(R)T-Vector (Novagen, Madison, WI, USA). The nucleotide sequences were determined by the dideoxy chain termination method using a Dye Primer Cycle Sequencing Kit (Perkin Elmer, Foster City, CA, USA).
Results
Analysis of MLL/AF-4 fusion mRNA in cord blood and t(4;11) leukemic cells
We analyzed the expression of MLL/AF-4 fusion mRNA in 65 samples of cord blood MNCs by nested PCR. Although no PCR product was obtained in any of the cord blood samples by the first-round PCR, positive bands were detected in three samples by the second-round PCR (CB 34, 38 and 55) (Figure 2a) . In leukemic cells obtained from one patient with t(4;11) infant leukemia, two different sizes of products were amplified. Figure 2b shows the results of the sequence analysis of these PCR products. Two different forms of MLL/AF-4 fusion mRNA were obtained in the t(4;11) leukemic cells. The breakpoint of these products were the 3′ end of MLL exon 6 or exon 7 and the 5′ end of AF-4 exon 4. In CB34 and CB38, however, the 5′ end of AF-4 exon 5 in-frame fused to the 3′ end of AF-4 exon 11. In CB55, the 5′ end of AF-4 exon 4 also in-frame fused to the 3′ end of AF-4 exon 11. It is likely that the binding of primer-MLLS2 and AF-4 exon 11 was due to misannealing, because of the high homology (six of eight base pairs) between the 3′ end of primer-MLLS2 and the binding site of AF-4 exon 11.
In-frame fusion of exon 11 and exon 4/5 in AF-4 in cord blood and t(4;11) leukemic cells
To confirm the fusion transcripts of AF-4 exon 11 and exon 4 or 5, a PCR using primer-AF4S3 and primer-AF4AS2 was performed for a second-round PCR. Figure 3 shows PCR products from representative cord blood samples and t(4;11) leukemic cells. As shown, two different sizes of PCR products were obtained, not only in several cord blood samples (including the above three samples) but also in t(4;11) leukemic cells. With the sequence analysis, in-frame fusion transcripts of AF-4 exon 11 and exon 4 or 5 were obtained; the smaller-sized PCR product was the transcript of exon 11 and exon 4, and the larger-sized was the transcript of exon 11 and Table 1 . A total of 20 samples of cord blood (30.8%) showed one of the forms, while the fusion was not observed in any sample of peripheral blood. We also analyzed leukemic cells with t(4;11), and four of the six samples including RS4;11 showed one form of transcript of the AF-4 gene (Table 1, Figure 4 ). The presence of these fusion tran- scripts was also confirmed by PCR using primer-AF4S2 and primer-AF4AS1 as the first-round PCR (data not shown).
To examine whether these fusion transcripts are limited to fetal hematopoietic cells, HEL, a cell line derived from fetal fibroblasts, was used for the detection of the fusion transcripts of the AF-4 gene. However, no PCR product was amplified with primer-AF4S3 and primer-AF4AS2 for nested PCR (data not shown).
Discussion
Recent studies of identical leukemic twins with shared clonal rearrangements of the MLL gene have revealed evidence of a mutational origin of infant leukemia during pregnancy. [19] [20] [21] Although the MLL gene has many different translocational partners, the AF-4 gene is specifically rearranged with the MLL gene. A recent study which showed the high expression of AF-4 in placenta suggested that the AF-4 gene may be upregulated in immature cells at early development. 24 It may be possible that instability of the AF-4 gene during fetal development renders it prone to breakage, and thus available for an illegitimate recombination with another gene.
In this study, we first analyzed the presence of the MLL/AF-4 rearrangement in cord blood, which is a representative site of fetal hematopoiesis. For the detection of the MLL/AF-4 rearrangement, a nested PCR was performed as described in several previous studies. 23, 25, 26 We detected two chimeric mRNAs from leukemic cells in one patient with t(4;11), with identical breakpoints as previously described. 14, 23 Two or three chimeric mRNA generated by the alternative splicing at the MLL or AF-4 genes were also detected in all t(4;11) leukemic cells, as reported in some cases of t(4;11) infant leukemia. 23, 25, 27 It is of interest that PCR products were also obtained in three of the 65 cord blood samples. The sequence analysis showed that these were not MLL/AF-4 fusion mRNA, but rather the in-frame fusion transcripts of exon 11 and exon 4 or 5 of the AF-4 gene.
To confirm the in-frame fusions of the AF-4 gene in the cord blood samples, another PCR was then performed using primers for AF-4 exon 11 and exon 5, and a high frequency of samples containing a fusion transcript of exon 11 and exon 4 a Four samples had both forms of transcripts of AF-4.
Figure 4
Analysis of leukemic cells with t(4;11). (a) PCR was also performed to detect fusion transcripts of exon 11 and exon 4/5 in five leukemic cells with t(4;11) and RS4;11. Two different sizes of PCR products were also obtained in four of the six samples. (b) All of these samples showed two or three forms of MLL/AF4 fusion mRNA by PCR using primer-MLLS2 and primer-AF4AS2. Lanes 1, 2, 3, 4 and 5, fresh leukemic cells with t(4;11); RS4;11, t(4;11) leukemic cell line; M, marker.
or 5 was observed in the cord blood as well as in leukemic cells with t(4;11), compared with the normal peripheral blood samples. The breakpoints of AF-4 were the 5′ end of exon 4 or 5, 12 and were identical to those observed in the majority of leukemic samples with t(4;11). 10, 25, 26, 28 Two hypotheses, the 'hotspot hypothesis' and the 'selection hypothesis', have been advocated as an explanation of how the MLL gene rearrangement is involved in leukemogenesis. 1, 12 A significant relationship between topoisomerase II (topo II) consensus binding sites and breakpoints of the MLL gene in patients with therapyrelated acute myeloid leukemia has been shown. 8, 29 It is suggested that an in utero exposure to substances which have some similarity to topo II inhibitors is also associated with the occurrence of infant leukemia. 1 We therefore examined topo II consensus binding sites in the AF-4 gene. 12 When we used the criteria for topo II consensus binding sites according to the previous reports, 29, 30 two matched sites were identified in intron 3, while no site was found in intron 4 or intron 11. Although several relatively homologous (80% homology) sites were identified in exon 11 or intron 11, the relationship between topo II binding sites and the fusion transcripts observed in the present study remains unresolved.
It may be that the selection of the product is responsible for the present results. Perhaps the exon 11/exon 4 or 5 product is the only combination that keeps critical exons in frame, or the only one that contains a critical function domain, whatever the function of this fusion product may be. Of interest is the finding that the transcriptional transactivation domain of the AF-4 gene is retained in the fusion transcripts observed in the present study. 13 Although we could not determine whether the fusions of AF-4 were the result of a duplication or of an insertion of the gene, the duplication of the gene is most likely since two exons (exon 11 and exon 4 or 5) were found to be in-frame fused to each other. In several cases of de novo acute myeloid leukemia with trisomy 11, a partial tandem duplication of the MLL gene was recently identified. 31, 32 Regarding the potential function(s) of the protein of the fusion transcripts of AF-4, since most of the leukemic cells with t(4;11) showed the same fusion transcripts as those in the cord blood, the protein may function as a potent transcription transactivator because of the duplication of the domain. The present findings may also indicate that if this fusion transcript has a function, it functions at the particular stage of development where the leukemic cells are 'frozen'. It may not have anything to do with the leukemia, but rather with the function of the normal AF-4 gene and protein, which is unknown.
Introns of eukaryotic genes are usually categorized as type 0, 1 or 2 introns depending on their phase, ie the position of their 5′ boundary within a triplet of the protein coding sequence. 12 Type 0 introns interrupt the reading frame between two triplets, and the boundaries of type 1 and 2 introns are located after the first and second nucleotide of a triplet, respectively. 33 Structural alterations of the AF-4 gene resulting from recombinations within introns of the same type will produce variants of the protein with a preserved open reading frame. 34 The breakpoints of AF-4 in infant leukemia with t(4;11) were recently demonstrated to always be present in intron type 0; the majority of the breakpoints are located in introns 3 and 4, and a few are in intron 5. 12 Interestingly, the introns in the breakpoint region of the MLL gene are also type 0, flanked on both sides by introns of a different type. 34 The type of the 3′ non-translated region of exon 11 is also type 0, which may support the significance of the fusion transcript of exon 11 and exon 4/5 of AF-4 gene in the production of functional proteins. Other introns such as introns 10, 13 and 15 are also type 0 and therfore represent a potential target for in-frame fusion with exon 4/5 of the AF-4 gene. We also examined the possibility of the recombination with other exon types in the AF-4 gene; all of the recombinations with introns of different types included the stop codon after the short reading frame (data not shown).
We showed the possibility that the in-frame fusion of AF-4 is a fetal-period event only in hematopoietic cells. A new gene family encoding nuclear proteins including AF-4, LAF-4 and FMR-2 was recently proposed. 12, 13 Nuclear localization was demonstrated for both AF-4 and LAF-4 protein. LAF-4 expression is found to be highest in lymphoid cells, 13 whereas the AF-4 gene is widely expressed in normal tissues. 35 Considering that all of the controls enrolled in the present study were infants or young children, it is likely that AF-4 expression is higher during the fetal period in hematopoietic cells.
In conclusion, we found the fusion transcripts of exon 11 and exon 4 or 5 of the AF-4 gene in cord blood, as well as in leukemic cells with t(4;11). The instability of the AF-4 gene in the fetal period may precede the MLL/AF-4 rearrangement in infant leukemia. Further investigations of partner genes of MLL are necessary to clarify leukemogenesis involving 11q23 translocations.
